The stock of Novavax Inc (NVAX) followed a bearish pattern in the after-market after releasing its financial outlook for Q4 and FY21. In the after-market, NVAX lost 7.04% to $77.5. NVAX closed the regular trading session at $83.37, gaining 2.13% from the previous trading session. The market capitalization of NVAX is $6.30 billion with 75.61 million shares pending.
NVAX fiscal 2021
On 28 February 2022, Novavax Inc released the financial performance for its Q4 and FY21, which concluded on 31 December 2021. Some important points are
- The revenue for NVAX reduced by 20.5% to $222.2 million in Q4 of FY21 compared to $279.6 million in the corresponding period of last year. The yearly revenue grew by 141% from $475.5 million in 2020 to $1.14 billion in 2021.
- The total loss of the company was reported to be $846.2 million in Q4 of FY21 in contrast to $177.5 million in Q4 of FY20. This marks a growth of 376.6% in the loss. The yearly loss was also up by 316.9% to $1.7 billion in 2021 versus $418.2 million in 2020.
- The loss of $11.18 and $23.44 per stock in Q4 and FY21, respectively.
Novavax Inc (NVAX) started the vaccine shipments worldwide in FY21. Also, NVAX extended clinical proof for NVX-CoV2373 across a few studies. Moreover, NVAX produced the COVID-19 vaccine, especially for the Omicron variant.
NVAX News
Also, On 28 February 2022, the company shared the expanded investigation from its Phase 3 clinical preliminary led in the United Kingdom (UK), showing a significant degree of adequacy for its protein-based COVID-19 vaccine, NVX-CoV2373. Further, the investigation showed immunization viability of 82.5% in assurance against all COVID-19 variants.
The president of Research and Development, Gregory M. Glenn, commented that vaccine offers the defense against symptomatic and asymptomatic infection of COVID-19. He further added that the vaccine keeps an undeniable degree of sturdy adequacy.
Fiscal 2022 outlook
Novavax Inc (NVAX) estimated the revenue for FY22 to be in the range of $4 billion to $5 billion.
